Anti-asparaginyl tRNA synthetase (Anti-KS) antibody-positive pneumonitis in a patient with immune checkpoint inhibitor treatment: A case report and literature review

Nobuhiro Oda; Okuto Koguchi; Hiroki Kontani; Jun Hayashi; Ryo Hazue; Yu Oyama; Ryo Rokutanda

doi:10.1093/mrcr/rxae043

Anti-asparaginyl tRNA synthetase (Anti-KS) antibody-positive pneumonitis in a patient with immune checkpoint inhibitor treatment: A case report and literature review

Mod Rheumatol Case Rep. 2024 Aug 5:rxae043. doi: 10.1093/mrcr/rxae043. Online ahead of print.

Authors

Nobuhiro Oda¹, Okuto Koguchi², Hiroki Kontani², Jun Hayashi³, Ryo Hazue¹, Yu Oyama², Ryo Rokutanda¹

Affiliations

¹ Department of Rheumatology, Kameda Medical Center, Kamogawa, Chiba, Japan.
² Department of Oncology, Kameda Medical Center, Kamogawa, Chiba, Japan.
³ Department of Pulmonology, Kameda Medical Center, Kamogawa, Chiba, Japan.

PMID: 39101392
DOI: 10.1093/mrcr/rxae043

Abstract

In recent years, the use of immune checkpoint inhibitors (ICI) has increased and there have been case reports of anti- aminoacyl tRNA synthetase (ARS) antibody syndrome during ICI treatment. However, these cases are limited, and their clinical characteristics are not fully understood. We report the first case of anti ARS antibody syndrome with KS antibody during ICI therapy. This report presents our case, along with a literature review of other anti ARS antibody syndrome cases that developed after ICI use, discussing their clinical characteristics and possible mechanisms of onset. Considering the widespread use of ICI in cancer therapy, we should aware of anti ARS antibody syndrome that develops during use of ICI .

Keywords: Immune checkpoint inhibitors; anti-tRNA synthetase (anti-ARS) antibody syndrome; immune-related adverse events (irAEs).

© Japan College of Rheumatology 2024. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site–for further information please contact journals.permissions@oup.com.